Source study unconfirmed
Story checked
Prehabilitation program reduces death risk for frail transplant candidates (opens in a new tab)
news-medical.net · 2026-10-21
Short answer
Source study unconfirmedStudy not confirmed.
The search did not establish a source study for this article. Its claims remain unverified; this does not mean they are incorrect.
These papers were considered as possible sources, but none could be confirmed as the study behind this story.
Share this check
The story
Prehabilitation program reduces death risk for frail transplant candidates
news-medical.net · 2026-10-21
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
No single source study could be confirmed.
The search identified related research but did not establish a single source study. Related papers are provided for context, not as verification of the article's claims.
View article claimsSearch result
Source study unconfirmed.
The search identified related research but did not establish a single source study. Related papers are provided for context, not as verification of the article's claims.
Source layer
The 2 papers the story cites
Source study separated from background citations.
The research anchor for the report.
- Also referencedpresented as the new finding
Personalized Prehabilitation: A Pathway to Improved Frailty Metrics and Survival in Liver Transplant Candidates
- Also referencedpresented as the new finding
Personalized Prehabilitation: A Pathway to Improved Frailty Metrics and Survival in Liver Transplant Candidates
Evidence layer
Claim by claim
The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 4Not checkedPatients whose frailty score improved by 0.4 points or more had a roughly 50% lower risk of dying while waiting for a transplant.View evidenceHide evidence
As statedroughly 50% lower risk
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 2 of 4Not checkedA new study from Northwestern Medicine and the University of Pittsburgh suggests that frailty can be significantly improved with a personalized, physician-led fitness program for transplant candidates.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 3 of 4Not checkedMore than 350 liver transplant candidates participated in a highly individualized workout and nutrition program, and nearly two-thirds of patients who attended at least three program visits lowered their frailty score by an average of nearly 0.4 points.View evidenceHide evidence
As statednearly 350; nearly two-thirds; nearly 0.4 points
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 4 of 4Not checkedThe study is titled 'Personalized Prehabilitation: A Pathway to Improved Frailty Metrics and Survival in Liver Transplant Candidates' and is scheduled to publish in Clinical Gastroenterology and Hepatology on Oct. 21.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Method layer
Study not confirmed.
The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.
Search results
Candidate papers, not confirmed sources.
Crossref, Europe PMC, PubMed · 33 candidate papers
Alcohol-associated liver disease
Clinical Gastroenterology and Hepatology · 2026 · Crossref
Atezolizumab plus Bevacizumab versus Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma Stratified by the CRAFITY Score: An International Multicenter Study.
2026 · Europe PMC
Reply
Clinical Gastroenterology and Hepatology · 2026 · Crossref
Recombinant Human Thrombopoietin Reduces the Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia.
2026 · Europe PMC
Correction
Clinical Gastroenterology and Hepatology · 2026 · Crossref